Based on that it appears highly likely that Collins St structured our last CR, rather than management. 1 for 2 Options with an exercise price set at CR price + 50%. The main difference is that the MEK deal was set at a 5-10% premium to the 5 day VWAP, probably to compensate for the higher gold price at this time.
Collins St sees the value in both GBR and MEK and have a minimum three-year time frame.
- Forums
- ASX - By Stock
- GBR
- General Discussion Topics
General Discussion Topics, page-3089
-
- There are more pages in this discussion • 493 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GBR (ASX) to my watchlist
|
|||||
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.77M |
Open | High | Low | Value | Volume |
4.8¢ | 4.9¢ | 4.6¢ | $42.72K | 902.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 125000 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.0¢ | 200000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 75000 | 0.046 |
1 | 42000 | 0.045 |
1 | 100000 | 0.044 |
1 | 232558 | 0.043 |
2 | 700000 | 0.042 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 200000 | 1 |
0.051 | 40000 | 1 |
0.052 | 245700 | 2 |
0.053 | 230000 | 1 |
0.056 | 109092 | 1 |
Last trade - 15.55pm 09/08/2024 (20 minute delay) ? |
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
GBR (ASX) Chart |